MA34084B1 - Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant - Google Patents
Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvantInfo
- Publication number
- MA34084B1 MA34084B1 MA35241A MA35241A MA34084B1 MA 34084 B1 MA34084 B1 MA 34084B1 MA 35241 A MA35241 A MA 35241A MA 35241 A MA35241 A MA 35241A MA 34084 B1 MA34084 B1 MA 34084B1
- Authority
- MA
- Morocco
- Prior art keywords
- type
- composition contains
- amyloid peptide
- beta amyloid
- plus virus
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des compositions comprenant une construction comprenant le peptide ?ß1-6 et un adjuvant pharmaceutiquement acceptable, destinées au traitement de patients souffrant de démence, en particulier la démence de type alzheimer. Dans un mode de réalisation, la construction contenant le peptide ?ß1-6 est constituée par une particule de type virus (vlp) du bactériophage à arn qß couplée chimiquement audit peptide ?ß1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10158273 | 2010-03-29 | ||
| PCT/EP2011/054735 WO2011120924A1 (fr) | 2010-03-29 | 2011-03-28 | Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34084B1 true MA34084B1 (fr) | 2013-03-05 |
Family
ID=42285305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35241A MA34084B1 (fr) | 2010-03-29 | 2011-03-28 | Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20130011431A1 (fr) |
| EP (1) | EP2552489A1 (fr) |
| JP (2) | JP6088422B2 (fr) |
| KR (1) | KR20130018407A (fr) |
| CN (2) | CN102834118A (fr) |
| AR (1) | AR080810A1 (fr) |
| AU (1) | AU2011234656B2 (fr) |
| BR (1) | BR112012024708A2 (fr) |
| CA (1) | CA2793580A1 (fr) |
| CL (1) | CL2012002685A1 (fr) |
| CO (1) | CO6630127A2 (fr) |
| EC (1) | ECSP12012180A (fr) |
| GT (1) | GT201200265A (fr) |
| IL (1) | IL221540B (fr) |
| MA (1) | MA34084B1 (fr) |
| MX (1) | MX2012011340A (fr) |
| NZ (1) | NZ601729A (fr) |
| PE (1) | PE20130642A1 (fr) |
| PH (1) | PH12012501683A1 (fr) |
| RU (1) | RU2603486C2 (fr) |
| SG (2) | SG183806A1 (fr) |
| TN (1) | TN2012000431A1 (fr) |
| TW (2) | TW201138805A (fr) |
| WO (1) | WO2011120924A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015017280A1 (fr) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Formulation de vaccins induisant une réponse immunitaire de type th2 |
| WO2015165961A1 (fr) | 2014-04-29 | 2015-11-05 | Affiris Ag | Traitement et prévention de la maladie d'alzheimer |
| JP6692755B2 (ja) * | 2014-04-29 | 2020-05-13 | アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ | アルツハイマー病（ａｄ）の処置および予防 |
| WO2015165971A1 (fr) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Traitement et prévention de la maladie d'alzheimer |
| CA2946929A1 (fr) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Traitement et prevention de la maladie d'alzheimer |
| WO2015165968A1 (fr) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Traitement et prévention de la maladie d'alzheimer |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| CA3150482A1 (fr) | 2019-09-16 | 2021-03-25 | Amgen Inc. | Methode de sterilisation externe d'un dispositif d'administration de medicament |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| FR2734484B1 (fr) * | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
| EP1006999A2 (fr) * | 1997-07-08 | 2000-06-14 | Chiron Corporation | Utilisation d'emulsions huile dans eau submicroniques avec des vaccins a adn |
| WO2003009869A1 (fr) * | 2001-07-26 | 2003-02-06 | Chiron Srl. | Vaccins comprenant des adjuvants aluminium et histidine |
| EP1524994B1 (fr) * | 2002-07-19 | 2011-04-27 | Cytos Biotechnology AG | Matrices d'antigenes amyloides beta1-6 |
| CN100409896C (zh) * | 2003-03-31 | 2008-08-13 | 姚志彬 | 一种老年性痴呆疫苗及其制备方法 |
| AU2005286475A1 (en) * | 2004-09-21 | 2006-03-30 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide |
| GB0424563D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| CN101318015A (zh) * | 2008-06-25 | 2008-12-10 | 中山大学 | 老年性痴呆重组蛋白疫苗及其制备方法 |
-
2011
- 2011-03-28 MA MA35241A patent/MA34084B1/fr unknown
- 2011-03-28 US US13/578,017 patent/US20130011431A1/en not_active Abandoned
- 2011-03-28 KR KR1020127025613A patent/KR20130018407A/ko not_active Ceased
- 2011-03-28 JP JP2013501791A patent/JP6088422B2/ja not_active Expired - Fee Related
- 2011-03-28 PH PH1/2012/501683A patent/PH12012501683A1/en unknown
- 2011-03-28 BR BR112012024708A patent/BR112012024708A2/pt not_active Application Discontinuation
- 2011-03-28 AR ARP110101001A patent/AR080810A1/es not_active Application Discontinuation
- 2011-03-28 TW TW100110650A patent/TW201138805A/zh unknown
- 2011-03-28 SG SG2012060554A patent/SG183806A1/en unknown
- 2011-03-28 MX MX2012011340A patent/MX2012011340A/es active IP Right Grant
- 2011-03-28 CN CN2011800162176A patent/CN102834118A/zh active Pending
- 2011-03-28 CN CN201410789825.6A patent/CN104436212A/zh active Pending
- 2011-03-28 PE PE2012001825A patent/PE20130642A1/es not_active Application Discontinuation
- 2011-03-28 SG SG10201505374TA patent/SG10201505374TA/en unknown
- 2011-03-28 NZ NZ601729A patent/NZ601729A/xx not_active IP Right Cessation
- 2011-03-28 RU RU2012145734/15A patent/RU2603486C2/ru not_active IP Right Cessation
- 2011-03-28 AU AU2011234656A patent/AU2011234656B2/en not_active Ceased
- 2011-03-28 CA CA2793580A patent/CA2793580A1/fr not_active Abandoned
- 2011-03-28 WO PCT/EP2011/054735 patent/WO2011120924A1/fr not_active Ceased
- 2011-03-28 TW TW104125184A patent/TW201618806A/zh unknown
- 2011-03-28 EP EP11711322A patent/EP2552489A1/fr not_active Withdrawn
-
2012
- 2012-08-20 IL IL221540A patent/IL221540B/en not_active IP Right Cessation
- 2012-08-30 TN TNP2012000431A patent/TN2012000431A1/en unknown
- 2012-09-25 EC ECSP12012180 patent/ECSP12012180A/es unknown
- 2012-09-26 GT GT201200265A patent/GT201200265A/es unknown
- 2012-09-27 CL CL2012002685A patent/CL2012002685A1/es unknown
- 2012-10-01 CO CO12171902A patent/CO6630127A2/es unknown
-
2014
- 2014-08-11 US US14/456,562 patent/US20140348871A1/en not_active Abandoned
-
2015
- 2015-06-26 US US14/751,492 patent/US20150297692A1/en not_active Abandoned
- 2015-12-17 US US14/972,187 patent/US20160101167A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115660A patent/JP2017008035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34084B1 (fr) | Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant | |
| EA201270824A1 (ru) | Соединения для уменьшения продукции бета-амилоида | |
| CL2011001098A1 (es) | Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras. | |
| EA201171388A1 (ru) | Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| MY181969A (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
| BR112012016797A2 (pt) | intensificador dinâmico de baixo utilizando compressor com equalizador incorporado | |
| CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
| EA201270225A1 (ru) | СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| SG179095A1 (en) | Novel assay for the detection of amyloid beta peptides | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| MX350046B (es) | Tratamientos para trastornos gastrointestinales. | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| WO2012021475A3 (fr) | ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS | |
| EP2769973A4 (fr) | Composé diterpène de type ingénane et composition pharmaceutique pour le traitement ou la prévention de maladies infectieuses virales le contenant | |
| EA201300421A1 (ru) | Комбинированная терапия для лечения инфекции hcv | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| EA201391097A1 (ru) | СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА | |
| BR112012013199A2 (pt) | composto, composição farmacêutica, e , uso de um composto |